Clinical characteristics of post-transplant lymphoproliferative disorders

The American Journal of Medicine

Volumn 97, Issue 1, 1994, Pages 14-24

  Morrison, Vicki A ^a   Dunn, David L ^a   Manivel, J Carlos ^a   Gajl Peczalska, K J ^a   Peterson, Bruce A ^a  

^a University of Minnesota   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AZATHIOPRINE; BLEOMYCIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; IFOSFAMIDE; LYMPHOCYTE ANTIBODY; PREDNISONE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOID HYPERPLASIA; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MALE; ORGAN TRANSPLANTATION; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; CHILD; FEMALE; HUMANS; IMMUNOPHENOTYPING; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0028359981     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/0002-9343(94)90043-4     Document Type: Article

References (54)

1. Five years' experience in renal transplantation with immunosuppressive drugs: survival, function, complications, and the role of lymphocyte depletion by thoracic duct fistula
2. Malignant lymphomas in transplantation patients
3. Malignancies associated with immunosuppressive or cytotoxic therapy
4. Epstein-Barr virus-induced lymphoma in a cardiac transplant patient
5. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporine-steroid therapy
6. Clinical spectrum of lymphoproliferative disorders in renal transplant recipients and evidence for the role of Epstein-Barr virus
7. Institute sponsored study of classification of non-Hodgkin's lymphoma
8. The clinico-pathological expressions of Epstein-Barr virus infection in lymphoid tissues
9. Report of the committee on Hodgkin's disease staging classification
10. B and T cell lymphomas: Analysis of blood and lymph nodes in 87 patients
11. Diversity of phenotypes of non-Hodgkin's malignant lymphomas
12. Hydroxydaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma
13. Chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone alone or with levamisole or with levamisole plus BCG for malignant lymphoma: a Southwest Oncology Group study
14. Long-term remission in diffuse histiocytic lymphoma treated with combination sequential chemotherapy
15. Treatment of advanced non-Hodgkin's lymphomas with favorable histologies
16. Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high-dose methotrexate alternating with standard agents (M-BACOD)
17. VACOP-B: 12 week chemotherapy for advanced stage diffuse large-cell lymphoma
18. Ifosfamide and etoposide as salvage therapy for non-Hodgkin's lymphoma
19. B-cell lymphoproliferative disorders in solid-organ transplant patients: detection of Epstein-Barr virus by in situ hybridization
20. Polymorphic diffuse B-cell hyperplasias and lymphomas in renal transplant recipients
21. T-cell lymphomas containing Epstein-Barr viral DNA in patients with chronic Epstein-Barr virus infections
22. The Epstein-Barr virus in the pathogenesis of post-transplant lymphoproliferative disorders
23. Epstein-Barr virus-induced B-cell lymphoma after renal transplantation
24. Epstein-Barr virus, immunodeficiency, and B cell lymphoproliferation
25. Epstein-Barr virus as an etiological agent in the pathogenesis of lymphoproliferative and aproliferative diseases in immune deficient patients
26. Epstein-Barr virus infections and DNA hybridization studies in post-transplantation lymphoma and lymphoproliferative lesions: the role of primary infection
27. Epstein-Barr virus and human diseases: recent advances in diagnosis
28. Epstein-Barr virus-determined clonality in post-transplant lymphoproliferative disease
29. Epstein-Barr virus induced polyclonal and monoclonal B-cell lymphoproliferative diseases occurring after renal transplantation
30. Cancers after cyclosporine therapy
31. Cancers following cyclosporine therapy
32. Increased frequency of posttransplant lymphomas in patients treated with cyclosporine, azathioprine, and prednisone
33. Increased frequency of posttransplant lymphomas in patients treated with cyclosporine, azathioprine, and prednisone
34. Cancer development in renal allograft recipients treated with conventional and cyclosporine immunosuppression
35. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac transplant recipients
36. Malignant lymphoma II. Prognostic factors and response to treatment of 473 patients at the National Cancer Institute
37. The influence of histologic type on survival in non-Hodgkin's lymphoma
38. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas
39. Treatment of advanced diffuse histiocytic lymphoma
40. Factors predicting for response and survival in adults with advanced non-Hodgkin's lymphoma
41. Prognostic factors for advanced diffuse histiocytic lymphoma following treatment with combination chemotherapy
42. Factors predicting long-term survival in diffuse mixed, histiocytic, or undifferentiated lymphoma
43. Reversibility of lymphomas and lymphoproliferative lesions developing undler cyclosporine-steroid therapy
44. Epstein-Barr virus polymorphic B-cell lymphoma associated with leukemia and with congenital immunodeficiences
45. Complete remission and possible immune tolerance after multidrug combination chemotherapy for cyclosporine-related lymphoma in a renal transplant recipient with acute pancreatitis
46. Lymphomas after cardiac transplantation: Houston experience and successful therapy
47. Effective combination chemotherapy for high-grade non-Hodgkin's lymphoma after cardiac transplant
48. ProMACE-CytaBOM induces durable complete remissions in post cardiac transplant lymphoma
49. Treatment of severe Epstein-Barr virus-induced lymphoproliferative syndrome with ganciclovir: two cases after solid organ transplantation
50. Treatment of B-cell lymphoproliferative disorders with interferon alfa and intravenous gamma globulin
51. Epstein-Barr virus-associated B-cell lymphoproliferative disorders in immunodeficiency: meeting the challenge
52. Epstein-Barr virus associated B-cell lymphoproliferative disorders following bone marrow transplantation
53. Treatment of severe Epstein-Barr virus-induced polyclonal B-lymphocyte proliferation of anti-B-cell monoclonal antibodies
54. Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation